Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

NCT00883558 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: Insulin Lispro
DRUG: regular human insulin
DRUG: recombinant human hyaluronidase PH20
DRUG: Insulin glargine

Sponsor

Halozyme Therapeutics